GeneDx Holdings Corp. (NASDAQ: WGS) details preliminary 2025 results and 2026 guidance in new update

Rhea-AI Filing Summary

GeneDx Holdings Corp. filed a report stating that it issued a press release on January 12, 2026 outlining its expectations for preliminary, unaudited revenue for the fourth quarter and full year 2025. The update also covers exome and genome test result volumes, GAAP and adjusted gross margin for the same periods, and levels of cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025.

The company additionally provided full year 2026 guidance and released an investor presentation prepared for the 44th Annual J.P. Morgan Healthcare Conference. These materials are furnished as exhibits and are not deemed filed for liability purposes under the securities laws or automatically incorporated into other regulatory documents.

0001818331false00018183312026-01-122026-01-120001818331us-gaap:CommonClassAMember2026-01-122026-01-120001818331us-gaap:WarrantMember2026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 12, 2026

Commission file number 001-39482

GeneDx Holdings Corp.

(Exact name of registrant as specified in its charter)

Delaware			85-1966622
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
333 Ludlow Street, North Tower; 6th Floor Stamford, Connecticut 06902
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (888) 729-1206

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Class A common stock, par value $0.0001 per share

WGS

The Nasdaq Stock Market LLC

Warrants to purchase one share of Class A common stock, each at an exercise price of $379.50 per share

WGSWW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

The information set forth in Item 7.01 below is incorporated by reference into this Item 2.02.

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) announcing the Company’s expectations regarding its preliminary, unaudited revenue for the fourth quarter and the year ended 2025, exome and genome test result volumes for the fourth quarter and the year ended 2025, GAAP and adjusted gross margin for the fourth quarter and the year ended 2025 and cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025. The Company also issued full year 2026 guidance. A copy of the Press Release is included with this Form 8-K for convenience and attached hereto as Exhibit 99.1. Also on January 12, 2026, the Company is furnishing as Exhibit 99.2 hereto a copy of the investor presentation to be used at the 44th Annual J.P. Morgan Healthcare Conference event.

The information furnished under Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No			Description
99.1			Press Release, dated January 12, 2026, regarding Preliminary 2025 Financial Results and Full Year 2026 Guidance
99.2			Investor Presentation, dated January 12, 2026
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						GENEDX HOLDINGS CORP.
Date:			January 12, 2026			By:			/s/ Katherine Stueland
						Name:			Katherine Stueland
						Title:			Chief Executive Officer

FAQ

What did GeneDx Holdings Corp. (WGS) disclose in this 8-K filing?

GeneDx Holdings Corp. disclosed that it issued a press release with preliminary, unaudited information on its fourth quarter and full year 2025 revenue, test volumes, gross margins, and cash balances, as well as full year 2026 guidance.

Which financial metrics did GeneDx (WGS) highlight for 2025?

The company highlighted preliminary, unaudited revenue for the fourth quarter and full year 2025, exome and genome test result volumes, GAAP and adjusted gross margin for those periods, and cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025.

Did GeneDx Holdings Corp. (WGS) provide guidance for 2026?

Yes. GeneDx Holdings Corp. stated that it issued full year 2026 guidance, described in the press release attached as Exhibit 99.1.

What exhibits are attached to the GeneDx (WGS) 8-K?

The exhibits include a press release dated January 12, 2026 regarding preliminary 2025 financial results and full year 2026 guidance (Exhibit 99.1), an investor presentation dated January 12, 2026 (Exhibit 99.2), and the cover page interactive data file (Exhibit 104).

Are the GeneDx (WGS) press release and presentation considered filed with the SEC?

The company states that the information furnished under Items 2.02 and 7.01, including Exhibit 99.1, is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically referenced.

What event related to investor outreach did GeneDx (WGS) mention?

GeneDx mentioned furnishing an investor presentation to be used at the 44th Annual J.P. Morgan Healthcare Conference as Exhibit 99.2.